Skip to main content Accessibility help
×
Home

Alprazolam and Exposure for Panic Disorder with Agoraphobia: Attribution of Improvement to Medication Predicts Subsequent Relapse

  • Metin Başoglu (a1), Isaac M. Marks (a1), Cengiz Kiliç (a1), Richard P. Swinson (a2), Homa Noshirvani (a3), Klaus Kuch (a2), Geraldine O'Sullivan (a4) and Chris R. Brewin (a5)...

Abstract

Patients with panic disorder plus agoraphobia had 8 weeks of drug treatment (alprazolam or placebo) plus psychological treatment (exposure or relaxation). At the end of treatment at week 8, 40 patients who had become much/very much improved rated how much their gains were attributable to medication or to their own efforts. During the tapering-off to week 16, and treatment-free follow-up to week 43, patients who at week 8 had attributed their gains to medication and felt less confident in coping without tablets had more severe withdrawal symptoms and greater loss of gains than did patients who at week 8 had attributed their gains to their own efforts during treatment. Baseline illness severity, greater age, higher expectations from drug treatment, and more side-effects of drugs during treatment all predicted more external attributions (i.e. to the effect of drugs) but did not independently predict relapse. Patients on alprazolam compared with placebo had more drug attributions. Though drug attributions predicted relapse in both alprazolam and placebo groups, predictions were stronger in the alprazolam group.

Copyright

Corresponding author

Correspondence

References

Hide All
Albus, M., Lecrubier, Y., Maier, W., et al (1990) Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatrica Scandinavica, 82, 359365.
Al-Kubaisy, T., Marks, I. M., Logsdail, S., et al (1992) Role of exposure homework in phobia reduction: A controlled study. Behaviour Therapy, 23, 599621.
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA.
Apelt, S., Schmauss, C. & Emrich, H. M. (1990) Preference for alprazolam as opposed to diazepam in benzodiazepine-dependent psychiatric inpatients. Pharmacopsychiatry, 23, 7072.
Ballenger, J. C., Burrows, O. D., Dupont, R. L., et al (1988) Alprazolam in panic disorder and agoraphobia: Results from a multi-center trial: I. Efficacy in short-term treatment. Archives of General Psychiatry, 45, 413422.
Barlow, D. H. (1988) Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York: Guilford Press.
BasLogblu, M., Marks, I. M. & SLenguun, S. (1992) A prospective study of panic and anxiety in agoraphobia with panic disorder. British Journal of Psychiatry, 160, 5764.
Beck, A. T., Ward, C. H., Mendelson, M., et al (1961) An inventory for measuring depression. Archives of General Psychiatry, 4, 561571.
Bradley, B. P., Gossop, M., Brewin, C. R., et al (1992) Attributions and relapse in opiate addicts. Journal of Consulting and Clinical Psychology, 60, 470472.
Brewin, C. R. (1988) Cognitive Foundations of Clinical Psychology. London and Hove: Lawrence Erlbaum.
Brewin, C. R. (1989) Cognitive change processes in psychotherapy. Psychological Review, 96, 379394.
Brewin, C. R. & Antaki, C. (1982) The role of attributions in psychological treatment. In Attributions and Psychological Change (eds Antaki, C. & Brewin, C.). London: Academic Press.
Cross-National Collaborative Panic Study, Second Phase Investigators (1992) Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine and placebo. British Journal of Psychiatry, 160, 191202.
Davison, G. C., Tsujimoto, R. N. & Glaros, A. G. (1973) Attribution and the maintenance of behaviour change in falling asleep. Journal of Abnormal Psychology, 82, 124133.
Deltito, J. A., Argyle, N., Buller, R., et al (1991) The sequence of improvement of the symptoms encountered in patients with panic disorder. Comprehensive Psychiatry, 32, 120129.
Derogatis, L. R., Lipman, R. S. & Covi, L. (1973) SCL-90: An outpatient psychiatric rating scale: preliminary report. Psychopharmacological Bulletin, 9, 1328.
Gelder, M. G. & Marks, I. M. (1966) Severe agoraphobia: a controlled trial. British Journal of Psychiatry, 112, 309312.
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Psychology, 32, 5055.
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Hollon, S. D., Shelton, R. C. & Loose, P. T. (1991) Cognitive therapy and pharmacotherapy for depression. Journal of Consulting and Clinical Psychology, 59, 8899.
Jeffrey, D. B. (1974) A comparison of the effects of external-control and self-control on the modification and maintenance of weight. Journal of Abnormal Psychology, 83, 404410.
Juergens, S. (1991) Alprazolam and diazepam: addiction potential. Journal of Substance Abuse and Treatment, 8, 4351.
Kelly, D., Guiguis, W., Frommer, E., et al (1970) Treatment of phobic states with antidepressants. British Journal of Psychiatry, 116, 387398.
Klein, D. F., Ross, D. C. & Cohen, P. (1987) Panic and avoidance in agoraphobia. Archives of General Psychiatry, 44, 377385.
Lesser, I. M., Rubin, R. T., Pecknold, J. C., et al (1988) Secondary depression in panic disorder and agoraphobia. Archives of General Psychiatry, 45, 437443.
Maier, W., Roth, M., Argyle, N., et al (1991) Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? European Archives of Psychiatry and Clinical Neurosciences, 241, 151158.
Margraf, J. & Ehlers, A. (1990) Biological models of panic disorder and agoraphobia: theory and evidence. In Handbook of Anxiety. Vol. 3 (eds Burrows, G. D., Roth, M. & Noyes, R. Jr), p. 79. Amsterdam: Elsevier.
Marks, I. M. & Matthews, A. M. (1979) Brief standard self-rating for phobic patients. Behavior Research and Therapy, 17, 263267.
Marks, I. M., Lblliott, P. T., BasLogblu, M., et al (1988) Clomipramine self-exposure and therapist aided exposure in obsessive-compulsive ritualisers. British Journal of Psychiatry, 152, 522534.
Marks, I. M., Swinson, R. P., BasLogblu, M., et al (1993) Alprazolam and exposure alone and combined panic disorder with agoraphobia: a controlled study in London and Toronto. British Journal of Psychiatry, 162, 776787.
Michelson, L. K. & Marchione, K. (1991) Behavioural, cognitive, and pharmacological treatments of panic disorder with agoraphobia: critique and synthesis. Journal of Consulting and Clinical Psychology, 59, 100114.
Noyes, R., Jr, Garvey, M. J., Cook, B., et al (1991) Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry, 148, 517523.
Pecknold, J. C., Swinson, R. P., Kuch, K., et al (1988) Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. III. Discontinuation effects. Archives of General Psychiatry, 45, 429436.
Petursson, H. & Lader, M. (1983) Benzodiazepine tolerance and withdrawal syndrome. In Advances in Psychopharmacology (eds Burrows, G. & Werry, J.). Greenwich, CT: JAI Press.
Rifkin, A., Pecknold, J. P., Swinson, R. P., et al (1990) Sequence of improvement in agoraphobia with panic attacks. Journal of Psychiatric Research, 24, 18.
Sonne, J. & Janoff, D. (1979) The effect of treatment attributions on the maintenance of weight reduction: A replication and extension. Cognitive Therapy and Research, 3, 389397.
Wolpe, J. & Lazarus, A. (1966) Behaviour Therapy Techniques. Oxford: Pergamon.

Alprazolam and Exposure for Panic Disorder with Agoraphobia: Attribution of Improvement to Medication Predicts Subsequent Relapse

  • Metin Başoglu (a1), Isaac M. Marks (a1), Cengiz Kiliç (a1), Richard P. Swinson (a2), Homa Noshirvani (a3), Klaus Kuch (a2), Geraldine O'Sullivan (a4) and Chris R. Brewin (a5)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Alprazolam and Exposure for Panic Disorder with Agoraphobia: Attribution of Improvement to Medication Predicts Subsequent Relapse

  • Metin Başoglu (a1), Isaac M. Marks (a1), Cengiz Kiliç (a1), Richard P. Swinson (a2), Homa Noshirvani (a3), Klaus Kuch (a2), Geraldine O'Sullivan (a4) and Chris R. Brewin (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *